CVRX Key Statistics, Chart & Performance
The current stock price of CVRX is 9.99 USD. In the past month the price decreased by -6.81%. In the past year, price decreased by -34.79%.
CVRX Latest News, Press Relases and Analysis
CVRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.66 | 222.87B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.23 | 207.51B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.36 | 150.19B | ||
| SYK | STRYKER CORP | 28.48 | 143.40B | ||
| IDXX | IDEXX LABORATORIES INC | 60.8 | 61.33B | ||
| BDX | BECTON DICKINSON AND CO | 13.56 | 56.03B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.78 | 50.38B | ||
| RMD | RESMED INC | 25.84 | 37.33B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.42 | 36.42B | ||
| DXCM | DEXCOM INC | 33.17 | 24.19B | ||
| PODD | INSULET CORP | 71.96 | 23.13B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12 | 19.23B |
Related stock screener links
About CVRX
Company Profile
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 206 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Company Info
CVRX INC
9201 West Broadway Avenue, Suite 650
Minneapolis MINNESOTA US
CEO: Nadim Yared
Employees: 206
Phone: 17634162850
CVRX INC / CVRX FAQ
Can you describe the business of CVRX INC?
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 206 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
What is the stock price of CVRX INC today?
The current stock price of CVRX is 9.99 USD. The price increased by 1.52% in the last trading session.
Does CVRX stock pay dividends?
CVRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVRX stock?
CVRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting CVRX stock to perform?
13 analysts have analysed CVRX and the average price target is 12.24 USD. This implies a price increase of 22.52% is expected in the next year compared to the current price of 9.99.
What is the employee count for CVRX stock?
CVRX INC (CVRX) currently has 206 employees.
What is CVRX INC worth?
CVRX INC (CVRX) has a market capitalization of 261.84M USD. This makes CVRX a Micro Cap stock.
CVRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CVRX. When comparing the yearly performance of all stocks, CVRX is a bad performer in the overall market: 64.24% of all stocks are doing better.
CVRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVRX. Both the profitability and financial health of CVRX have multiple concerns.
CVRX Financial Highlights
Over the last trailing twelve months CVRX reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 25.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.73% | ||
| ROE | -108.26% | ||
| Debt/Equity | 1.03 |
CVRX Forecast & Estimates
13 analysts have analysed CVRX and the average price target is 12.24 USD. This implies a price increase of 22.52% is expected in the next year compared to the current price of 9.99.
For the next year, analysts expect an EPS growth of 23.03% and a revenue growth 9.98% for CVRX